Journal article

International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function

Nicholas M Barnes, Gerard P Ahern, Carine Becamel, Joel Bockaert, Michael Camilleri, Severine Chaumont-Dubel, Sylvie Claeysen, Kathryn A Cunningham, Kevin C Fone, Michael Gershon, Giuseppe Di Giovanni, Nathalie M Goodfellow, Adam L Halberstadt, Rachel M Hartley, Gherici Hassaine, Katharine Herrick-Davis, Ruud Hovius, Enza Lacivita, Evelyn K Lambe, Marcello Leopoldo Show all

PHARMACOLOGICAL REVIEWS | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | Published : 2021

Abstract

5-HT receptors expressed throughout the human body are targets for established therapeutics and various drugs in development. Their diversity of structure and function reflects the important role 5-HT receptors play in physiologic and pathophysiological processes. The present review offers a framework for the official receptor nomenclature and a detailed understanding of each of the 14 5-HT receptor subtypes, their roles in the systems of the body, and, where appropriate, the (potential) utility of therapeutics targeting these receptors. SIGNIFICANCE STATEMENT: This review provides a comprehensive account of the classification and function of 5-hydroxytryptamine receptors, including how they..

View full abstract

Grants

Awarded by Ministry of Defence


Awarded by Fondation pour la Recherche Medicale


Awarded by l'Agence nationale de la recherche (France)


Awarded by Fondation Vaincre Alzheimer


Awarded by National Institutes of Health National Institute on Drug Abuse


Awarded by Consejo Nacional de Ciencia y Tecnologia


Awarded by National Health and Medical Research Council (Australia)


Funding Acknowledgements

This work was supported by Ministry of Defence [JFC7a/00018], the University of Birmingham and Celentyx Ltd. Centre national de la recherche scientifique (France), the Institut national de la sante et de la recherche medicale (France), University of Montpellier, Fondation pour la Recherche Medicale [Grant DPA20140629800] and l'Agence nationale de la recherche (France) [Grants ANR-11-BSV4-008-01 "SERO6COGNET," ANR-12-BSV4-0008-01 "ADAMGUARD" and ANR-17-CE16-0013-01 "StopSero6TOR," ANR-17-CE16-0010 "Sero6Dev"], France Alzheimer, Languedoc Roussillon region, Fondation Plan Alzheimer and Fondation Vaincre Alzheimer [Grant 12721 and LECMA FR-15072], National Institutes of Health National Institute on Drug Abuse [Grants T32 DA007287, P50 DA033935, and K05 DA020087], Banting and Best Canada Graduate Scholarship from the Canadian Institutes of Health Research, South-Eastern Norway Regional Health Authority, The Norwegian Council on Cardiovascular Diseases, The Research Council of Norway, The Kristian Gerhard Jebsen Foundation, Anders Jahre's Foundation for the Promotion of Science, The Family Blix foundation, The Simon Fougner Hartmann Family Foundation and the University of Oslo, the European Research Council [Grant ERC-2014-StG PentaBrain], Consejo Nacional de Ciencia y Tecnologia [Grant CONACyT, No. 219707], University of Melbourne, Hallmark initiative, National Health and Medical Research Council (Australia) [Grants APP1105284 and APP1105332], Alzheimer's Association, and Royal Australian College of General Practitioners Ltd foundation (Australia).